122 related articles for article (PubMed ID: 8013893)
1. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes.
Vincent-Viry M; Pontes ZB; Gueguen R; Galteau MM; Siest G
Genet Epidemiol; 1994; 11(2):115-29. PubMed ID: 8013893
[TBL] [Abstract][Full Text] [Related]
2. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity.
Cribb AE; Isbrucker R; Levatte T; Tsui B; Gillespie CT; Renton KW
Pharmacogenetics; 1994 Jun; 4(3):166-70. PubMed ID: 7920698
[TBL] [Abstract][Full Text] [Related]
3. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
McQuilkin SH; Nierenberg DW; Bresnick E
Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
[TBL] [Abstract][Full Text] [Related]
4. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.
Relling MV; Lin JS; Ayers GD; Evans WE
Clin Pharmacol Ther; 1992 Dec; 52(6):643-58. PubMed ID: 1458773
[TBL] [Abstract][Full Text] [Related]
5. Human N-acetylation genotype determination with urinary caffeine metabolites.
Kilbane AJ; Silbart LK; Manis M; Beitins IZ; Weber WW
Clin Pharmacol Ther; 1990 Apr; 47(4):470-7. PubMed ID: 2328555
[TBL] [Abstract][Full Text] [Related]
6. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping.
Tang BK; Kadar D; Qian L; Iriah J; Yip J; Kalow W
Clin Pharmacol Ther; 1991 Jun; 49(6):648-57. PubMed ID: 2060254
[TBL] [Abstract][Full Text] [Related]
7. Acetylation polymorphism of caffeine in a Japanese population.
Hashiguchi M; Ebihara A
Clin Pharmacol Ther; 1992 Sep; 52(3):274-6. PubMed ID: 1526084
[TBL] [Abstract][Full Text] [Related]
8. Caffeine as a potential indicator for acetylator status.
Rankin RB; Hudson SA; Fell AF
J Clin Pharm Ther; 1987 Feb; 12(1):47-51. PubMed ID: 3449563
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of a caffeine test for determining the phenotype of N-acetyltransferase].
Gascon MP; Leemann T; Dayer P
Schweiz Med Wochenschr; 1987 Dec; 117(49):1974-6. PubMed ID: 3423781
[TBL] [Abstract][Full Text] [Related]
10. Caffeine acetylator phenotyping during maturation in infants.
Pariente-Khayat A; Pons G; Rey E; Richard MO; D'Athis P; Moran C; Badoual J; Olive G
Pediatr Res; 1991 May; 29(5):492-5. PubMed ID: 1896253
[TBL] [Abstract][Full Text] [Related]
11. Polymorphism of theophylline metabolism in man.
Miller CA; Slusher LB; Vesell ES
J Clin Invest; 1985 May; 75(5):1415-25. PubMed ID: 4039734
[TBL] [Abstract][Full Text] [Related]
12. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements.
Tang BK; Zhou Y; Kadar D; Kalow W
Pharmacogenetics; 1994 Jun; 4(3):117-24. PubMed ID: 7920691
[TBL] [Abstract][Full Text] [Related]
13. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.
Butler MA; Lang NP; Young JF; Caporaso NE; Vineis P; Hayes RB; Teitel CH; Massengill JP; Lawsen MF; Kadlubar FF
Pharmacogenetics; 1992 Jun; 2(3):116-27. PubMed ID: 1306111
[TBL] [Abstract][Full Text] [Related]
14. Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites.
Kadlubar FF; Talaska G; Butler MA; Teitel CH; Massengill JP; Lang NP
Prog Clin Biol Res; 1990; 340B():107-14. PubMed ID: 2392442
[No Abstract] [Full Text] [Related]
15. Polymorphic N-acetylation of a caffeine metabolite.
Grant DM; Tang BK; Kalow W
Clin Pharmacol Ther; 1983 Mar; 33(3):355-9. PubMed ID: 6825389
[TBL] [Abstract][Full Text] [Related]
16. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.
Grant DM; Mörike K; Eichelbaum M; Meyer UA
J Clin Invest; 1990 Mar; 85(3):968-72. PubMed ID: 2312737
[TBL] [Abstract][Full Text] [Related]
17. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.
Nakajima M; Yokoi T; Mizutani M; Shin S; Kadlubar FF; Kamataki T
Cancer Epidemiol Biomarkers Prev; 1994; 3(5):413-21. PubMed ID: 7920209
[TBL] [Abstract][Full Text] [Related]
18. Maturation of AFMU excretion in infants.
Pons G; Rey E; Carrier O; Richard MO; Moran C; Badoual J; Olive G
Fundam Clin Pharmacol; 1989; 3(6):589-95. PubMed ID: 2613160
[TBL] [Abstract][Full Text] [Related]
19. Acetylator phenotypes of Saudi Arabians by a simplified caffeine metabolites test.
el-Yazigi A; Chaleby K; Martin CR
J Clin Pharmacol; 1989 Mar; 29(3):246-50. PubMed ID: 2723111
[TBL] [Abstract][Full Text] [Related]
20. Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers.
Muscat JE; Pittman B; Kleinman W; Lazarus P; Stellman SD; Richie JP
Biochem Pharmacol; 2008 Oct; 76(7):929-37. PubMed ID: 18703023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
